PDF(1430 KB)
Effect of Xiaoji Zhike oral liquid and ambroxol oral liquid in the treatment of mycoplasma pneumonia in children
YANG Ling
Shanghai Medical & Pharmaceutical Journal ›› 2023, Vol. 44 ›› Issue (24) : 15-18.
PDF(1430 KB)
PDF(1430 KB)
Effect of Xiaoji Zhike oral liquid and ambroxol oral liquid in the treatment of mycoplasma pneumonia in children
({{custom_author.role_en}}), {{javascript:window.custom_author_en_index++;}}Objective: To investigate the application effect of Xiaoji Zhike oral liquid and ambroxol oral liquid in the treatment of mycoplasma pneumonia in children. Methods: Fifty children with mycoplasma pneumonia who were treated at the People’s Hospital of Nanfeng County, Jiangxi Province from June 2020 to September 2022 were collected, and a random number table method was used to divide them into an observation group and a control group with 25 cases each. Both groups were given basic treatment such as cough relieving and phlegm resolving. On this basis, the control group was treated with ambroxol oral solution: 6 months to 2 years old, 1.5 mL/dose; 2-6 years old, 2.5 mL/time; 6-12 years old, 5 mL/time; 3 times/d. The observation group was treated with Xiaoji Zhike oral liquid on the basis of the control group: under 1 year old, 5 mL/dose; 1-2 years old, 10 mL/time; 3-4 years old, 15 mL/time; over 5 years old, 20 mL/time; 3 times/d. Both groups were treated for 2 weeks. The time for body temperature recovering normal, hospitalization time, symptom disappearance time, humoral immune level, serum inflammatory indicators, and therapeutic effect were observed. Results: The time for body temperature recovering normal and hospitalization time in the observation group were lower than those in the control group(P<0.05). The disappearance times of cough, lung lesions, and lung rales in the observation group were earlier than those in the control group(P<0.05). After intervention, the levels of CD3+and CD4+ in both groups were significantly increased compared to before treatment, and the observation group was higher than the control group(P<0.05); the levels of IgM and IgA significantly decreased, and the observation group was lower than the control group(P<0.05). After intervention, the levels of hs-CRP and IL-6 in both groups were lower than those in the same group before intervention, and the observation group was lower than those in the control group(P<0.05); the IL-10 level was higher than those before the intervention in the same group, and the observation group was higher than the control group(P<0.05). The total effective rate in the observation group was 96.00%(24/25), which was higher than 72.00%(18/25) in the control group(P<0.05). Conclusion: The application effect of Xiaoji Zhike oral liquid combined with ambroxol oral liquid in the treatment of mycoplasma pneumonia in children is effective, which can shorten the time for children’s body temperature recovering normal, hospitalization time, symptom disappearance time, and improve humoral immunity level, and enhance the treatment effect.
mycoplasma pneumonia in children / Xiaoji Zhike oral liquid / ambroxol oral liquid / application effect {{custom_keyword}} /
表1 两组体温恢复正常时间、住院时间以及症状消失时间对比 （ |
| 分组 | 体温恢复正常时间 | 住院时间 | 症状消失时间 | ||
|---|---|---|---|---|---|
| 咳嗽 | 肺部病灶 | 肺部啰音 | |||
| 观察组（n=25） | 6.23±1.22 | 7.26±1.22 | 1.58±0.42 | 3.11±0.74 | 4.11±0.98 |
| 对照组（n=25） | 8.33±1.35 | 10.58±1.69 | 3.96±0.87 | 4.99±0.97 | 6.02±1.34 |
| t值 | 10.887 | 17.211 | 28.333 | 12.703 | 9.745 |
| P值 | <0.05 | <0.05 | <0.05 | <0.05 | <0.05 |
表2 两组体液免疫水平对比 （ |
| 分组 | CD3+ | CD4+ | IgM | IgA |
|---|---|---|---|---|
| 观察组（n=25） | ||||
| 干预前 | 1.19±0.15 | 0.72±0.12 | 2.74±0.24 | 2.13±0.31 |
| 干预后 | 2.98±0.34 | 1.56±0.35 | 1.21±0.15 | 0.82±0.14 |
| t值 | 59.667 | 35.000 | 31.875 | 21.129 |
| P值 | <0.05 | <0.05 | <0.05 | <0.05 |
| 对照组（n=25） | ||||
| 干预前 | 1.18±0.13 | 1.74±0.14 | 2.76±0.21 | 2.15±0.29 |
| 干预后 | 2.25±0.29 | 1.63±0.29 | 2.03±0.19 | 1.41±0.24 |
| t值 | 41.154 | 3.929 | 17.381 | 12.759 |
| P值 | <0.05 | <0.05 | <0.05 | <0.05 |
| t组间干预后 | 10.735 | 1.000 | 27.333 | 21.071 |
| P组间干预后 | <0.05 | <0.05 | <0.05 | <0.05 |
表3 两组血清炎症指标对比 （ |
| 分组 | hs-CRP/（g/L） | IL-6/（ng/L） | IL-10/（ng/L） |
|---|---|---|---|
| 观察组（n=25） | |||
| 干预前 | 35.77±4.98 | 95.38±5.22 | 96.33±10.22 |
| 干预后 | 8.99±0.46 | 52.04±4.69 | 175.98±12.14 |
| t值 | 26.888 | 41.513 | 38.968 |
| P值 | <0.05 | <0.05 | <0.05 |
| 对照组（n=25） | |||
| 干预前 | 35.79±5.21 | 95.44±5.09 | 96.28±8.76 |
| 干预后 | 15.64±2.11 | 79.64±8.15 | 126.48±11.12 |
| t值 | 19.338 | 15.521 | 17.237 |
| P值 | <0.05 | <0.05 | <0.05 |
| t组间干预后 | 72.283 | 29.424 | 20.387 |
| P组间干预后 | <0.05 | <0.05 | <0.05 |
表4 两组疗效对比 [n（%）] |
| 分组 | 治愈 | 显效 | 有效 | 无效 | 总有效 |
|---|---|---|---|---|---|
| 观察组 （n=25） | 15（60.00） | 7（28.00） | 2（8.00） | 1（4.00） | 24（96.00） |
| 对照组 （n=25） | 7（28.00） | 8（32.00） | 3（12.00） | 7（28.00） | 18（72.00） |
| χ2值 | 6.247 | ||||
| P值 | <0.05 |
| [1] |
郑地松. 小儿消积止咳口服液联合氨溴索注射液治疗小儿痰热壅肺型支原体肺炎的临床疗效[J]. 临床合理用药杂志, 2022, 15(3): 133-135.
{{custom_citation.content}}
{{custom_citation.annotation}}
|
| [2] |
刘军燕. 阿奇霉素联合小儿消积止咳口服液治疗小儿支原体肺炎的临床疗效和安全性[J]. 心理医生, 2018, 24(3): 102-103.
{{custom_citation.content}}
{{custom_citation.annotation}}
|
| [3] |
The epidemiology of Mycoplasma pneumoniae (Mp) among US children (<18 years) hospitalized with community-acquired pneumonia (CAP) is poorly understood.In the Etiology of Pneumonia in the Community study, we prospectively enrolled 2254 children hospitalized with radiographically confirmed pneumonia from January 2010-June 2012 and tested nasopharyngeal/oropharyngeal swabs for Mp using real-time polymerase chain reaction (PCR). Clinical and epidemiological features of Mp PCR-positive and -negative children were compared using logistic regression. Macrolide susceptibility was assessed by genotyping isolates.One hundred and eighty two (8%) children were Mp PCR-positive (median age, 7 years); 12% required intensive care and 26% had pleural effusion. No in-hospital deaths occurred. Macrolide resistance was found in 4% (6/169) isolates. Of 178 (98%) Mp PCR-positive children tested for copathogens, 50 (28%) had ≥1 copathogen detected. Variables significantly associated with higher odds of Mp detection included age (10-17 years: adjusted odds ratio [aOR], 10.7 [95% confidence interval {CI}, 5.4-21.1] and 5-9 years: aOR, 6.4 [95% CI, 3.4-12.1] vs 2-4 years), outpatient antibiotics ≤5 days preadmission (aOR, 2.3 [95% CI, 1.5-3.5]), and copathogen detection (aOR, 2.1 [95% CI, 1.3-3.3]). Clinical characteristics were non-specific.Usually considered as a mild respiratory infection, Mp was the most commonly detected bacteria among children aged ≥5 years hospitalized with CAP, one-quarter of whom had codetections. Although associated with clinically nonspecific symptoms, there was a need for intensive care in some cases. Mycoplasma pneumoniae should be included in the differential diagnosis for school-aged children hospitalized with CAP.
{{custom_citation.content}}
{{custom_citation.annotation}}
|
| [4] |
朱翠华. 阿奇霉素联合小儿消积止咳口服液治疗小儿支原体肺炎的疗效观察[J]. 饮食保健, 2019, 6(37): 67-68.
{{custom_citation.content}}
{{custom_citation.annotation}}
|
| [5] |
{{custom_citation.content}}
{{custom_citation.annotation}}
|
| [6] |
罗林坚, 李兰芳, 蔡光华, 等. 阿奇霉素联合小儿消积止咳口服液治疗小儿支原体肺炎的临床疗效和安全性观察[J]. 中国处方药, 2020, 18(9): 130-132.
{{custom_citation.content}}
{{custom_citation.annotation}}
|
| [7] |
李勤英. 小儿消积止咳口服液辅助治疗肺炎支原体感染后慢性咳嗽患儿的疗效观察[J]. 实用中西医结合临床, 2020, 20(13): 81-82.
{{custom_citation.content}}
{{custom_citation.annotation}}
|
| [8] |
{{custom_citation.content}}
{{custom_citation.annotation}}
|
| [9] |
胡亚美, 江载芳. 诸福棠实用儿科学[M]. 7版. 北京: 人民卫生出版社, 2002: 1204-1206.
{{custom_citation.content}}
{{custom_citation.annotation}}
|
| [10] |
中华医学会儿科学分会呼吸学组, 《中华实用儿科临床杂志》编辑委员会. 儿童肺炎支原体肺炎诊治专家共识(2015年版)[J]. 中华实用儿科临床杂志, 2015, 30(17): 1304-1308.
{{custom_citation.content}}
{{custom_citation.annotation}}
|
| [11] |
胡跃华. 阿奇霉素联合小儿消积止咳口服液治疗小儿支原体肺炎的疗效观察[J]. 中国社区医师, 2018, 34(13): 105-106.
{{custom_citation.content}}
{{custom_citation.annotation}}
|
| [12] |
{{custom_citation.content}}
{{custom_citation.annotation}}
|
| [13] |
齐占华. 阿奇霉素联合小儿消积止咳口服液治疗小儿支原体肺炎的效果观察[J]. 中国实用医药, 2018, 13(32): 128-129.
{{custom_citation.content}}
{{custom_citation.annotation}}
|
| [14] |
黄锦娟, 洛阳巨. 小儿消积止咳口服液联合阿奇霉素治疗小儿支原体肺炎的疗效[J]. 中国合理用药探索, 2018, 15(12): 60-62.
{{custom_citation.content}}
{{custom_citation.annotation}}
|
| [15] |
李彦甫, 靳燕霞. 阿奇霉素联合小儿消积止咳口服液治疗支原体肺炎疗效观察[J]. 北方药学, 2018, 15(2): 38-39.
{{custom_citation.content}}
{{custom_citation.annotation}}
|
| [16] |
李晓红. 阿奇霉素联合小儿消积止咳口服液治疗小儿支原体肺炎的效果观察[J]. 中国农村卫生, 2018, 11(13): 44; 43.
{{custom_citation.content}}
{{custom_citation.annotation}}
|
| [17] |
裴哲. 小儿消积止咳口服液联合注射用炎琥宁治疗儿童支原体肺炎的临床效果[J]. 河南医学研究, 2018, 27(23): 4351-4352.
{{custom_citation.content}}
{{custom_citation.annotation}}
|
| {{custom_ref.label}} |
{{custom_citation.content}}
{{custom_citation.annotation}}
|
/
| 〈 |
|
〉 |
